Acute Nausea and Vomiting

Important Safety Information Full Prescribing Information

Acute Nausea & Vomiting

The first phase of chemotherapy-induced nausea and vomiting (CINV) is referred to as acute CINV.¹

Acute CINV occurs within the first 24 hours following chemotherapy administration, with the highest risk period occurring during the first 4 hours of treatment.¹ Many factors may contribute to the occurrence and severity of nausea. These factors include chemotherapy drug regimen, dose, schedule and route of administration.²

In addition, acute CINV is more likely to occur in cancer patients who have experienced nausea and vomiting after previous chemotherapy sessions, in females, in patients who drink little or no alcohol, and in patients less than 50 years of age.³

Indication

In adults, ALOXI^® (palonosetron HCl) injection 0.25 mg is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy, and acute nausea and vomiting associated with initial and repeat courses of highly emetogenic chemotherapy.

Important Safety Information

Aloxi is contraindicated in patients known to have hypersensitivity to the drug of any of its components
Most commonly reported adverse reactions in chemotherapy-induced nausea and vomiting include headache (9%) and constipation (5%)

For more information about ALOXI, please see Full Prescribing Information

References

National Cancer Institute. Overview. Available at: http://www.cancer.gov/cancertopics/pdq/supportivecare/nausea/HealthProfessional/page2. Accessed July 7, 2010.
National Cancer Institute. Acute/Delayed Nausea and Vomiting (Emesis) Etiology. Available at: http://www.cancer.gov/cancertopics/pdq/supportivecare/nausea/HealthProfessional/page6. Accessed March 29, 2010.
National Cancer Institute. General risk factors and etiologies. Available at: http://www.cancer.gov/cancertopics/pdq/supportivecare/nausea/HealthProfessional/page4. Accessed July 7, 2010.

Sitemap | Legal Notice and Disclaimers | Privacy

This information is intended for use by healthcare professionals in the United States only. Eisai Inc. recognizes that the Internet is a global communications medium; however, laws, regulatory requirements and medical practices for pharmaceutical products vary from country to country. The Prescribing Information included here is not appropriate for use outside the United States.